We first explored the alteration in cxcr6 gene in a merged cohort of low grade glioma (LGG) and GBM (TCGA, Cell 2016) and found a significant increase in patient months survival associated with cxcr6 deletion (median months survival 130.7 vs. 20.6 in normal cases, Log rank Test P-value 0.0339); we than looked at cxcr6 mRNA expression data in a cohort of Glioblastoma (TCGA, Cell 2013) and found a significant decrease in months survival associated with cxcr6 mRNA overexpression (median months survival 5.2 vs. 14 in normal cases, Log rank Test P-value 0.00417), Supplementary Figure 2. This evidence concerns the gene CXCR6 and low grade glioma.